A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Applying to University of Illinois Hospital and Health Sciences System /ID# 275345 · Chicago, Illinois
Answer a few short questions to share with the research team.